<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        16-468-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOYADA 5MG/5ML ORAL SOLUTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CAPTOPRIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        140.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MACARTHYS LABORATORIES Ltd T/A MARTINDALE PHARMACEUTICALS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MACARTHYS LABORATORIES Ltd T/A MARTINDALE PHARMACEUTICALS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 521]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Faisal Musaed El Seif Saudi Pharmaceutical Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MACARTHYS LABORATORIES Ltd T/A MARTINDALE PHARMACEUTICALS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09AA01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Noyada Oral Solution contains the active substance captopril which belongs to the group of&nbsp;medicines called Angiotensin Converting Enzyme (ACE) Inhibitors. ACE inhibitors work by helping to widen your<br />blood vessels, which then make it easier for your heart to pump blood through them.<br />Captopril is used to treat the following in adults, the elderly and children:<br />&bull; High blood pressure and certain heart conditions. If high blood pressure is left uncontrolled it can increase the<br />risk of heart disease or stroke. Captopril works by lowering your blood pressure which reduces this risk.<br />&bull; People whose heart no longer pumps blood as well as it once did. This condition is known as heart failure.<br />&bull; People who have recently suffered a heart attack. A heart attack happens once one of the major blood vessels<br />supplying blood to the heart muscle becomes blocked. This means that the heart does not receive the oxygen it<br />needs and the heart muscle becomes damaged.<br />&bull; Kidney disease in people with diabetes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Noyada Oral Solution if:<br />&bull; you are allergic (hypersensitive) to captopril, any other ACE inhibitors, or any of the other ingredients of this<br />medicine (listed in section 6 of this leaflet)<br />&bull; you or any members of your family have ever had a reaction which included swelling of the hands, lips, face or<br />tongue where the cause was unknown<br />&bull; you are more than 3 months pregnant (it is better to avoid Noyada Oral Solution in early pregnancy (see<br />Pregnancy section).<br />&bull; you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine<br />containing aliskiren<br />If any of the above applies to you or your child you should ask your doctor&rsquo;s advice before taking this medicine.<br />Warnings and precautions<br />Talk to your doctor or pharmacist or nurse before taking Noyada oral solution.<br />If you are taking any of the following medicines used to treat high blood pressure:<br />&bull; an angiotensin II receptor blocker (ARBs) (also known as sartans &ndash; for example valsartan, telmisartan, irbesartan),<br />in particular if you have diabetes-related kidney problems.<br />&bull; aliskiren.<br />Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in<br />your blood at regular intervals.<br />See also information under the heading &lsquo;Do not take Noyada Oral Solution&rsquo;.<br />You must tell your doctor if:<br />&bull; you think you are (or might become) pregnant. Noyada Oral Solution is not recommended in early pregnancy,<br />and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if<br />used at that stage (see pregnancy section)<br />&bull; you are breast-feeding or about to start breast-feeding<br />&bull; you are on a reduced-salt diet<br />&bull; you are taking diuretic (water tablets)<br />&bull; you have recently suffered from excessive vomiting or diarrhoea<br />&bull; you are undergoing dialysis<br />&bull; you have heart problems in particular problems with the valves of your heart<br />&bull; you suffer from liver disease<br />&bull; you have diabetes<br />&bull; you get swelling in your face, neck or throat<br />&bull; you get any changes in the colour of your skin or the whites of your eyes, you must see your doctor immediately<br />&bull; you are going to have an operation in hospital or you are going to the dentist<br />&bull; you get stomach pains &ndash; you need to tell your doctor you are taking Noyada Oral Solution<br />&bull; you feel ill, become aware of your heartbeat and get muscle weakness &ndash; you may have high amounts of<br />potassium in your blood, your doctor will perform a blood test to check this.<br />Immunosuppressant therapy<br />If you are receiving immunosuppressant therapy your doctor may carry out a number of tests during your<br />treatment with Noyada Oral Solution to make sure that you are showing no signs of an infection. If you begin to<br />have symptoms of an infection such as a sore throat or fever you should contact your doctor immediately.<br />Patients with kidney disease<br />If you suffer from kidney disease your doctor may carry out a number of tests both before and during your<br />treatment with Noyada Oral Solution to check the levels of protein in your urine.<br />Wasp sting desensitisation<br />If you are to have desensitisation treatment for wasp or bee stings you should tell the doctor who is treating<br />you that you are taking Noyada Oral Solution. In rare cases a serious allergic reaction can happen if you have<br />desensitisation treatment whilst taking this medicine.<br />Dialysis<br />If you are about to have treatment for the removal of cholesterol from your blood by a machine (called LDL<br />apheresis) you should tell your doctor you are taking Noyada Oral Solution. You may be given a different type of<br />dialysis whilst taking this medicine.<br />Blood and urine tests<br />Tell your doctor or nurse you are taking Noyada Oral Solution before you have any blood or urine tests as this<br />medicine may interfere with the results of some tests.<br />Ethnic differences<br />If you are Afro-Caribbean you may require higher doses of Noyada Oral Solution to reduce your blood pressure.<br />Taking other medicines and Noyada Oral Solution<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is<br />because Noyada Oral Solution can affect the way some other medicines work.</p><p>In addition to this some other medicines can also affect the way Noyada Oral Solution works. It is especially<br />important to tell your doctor if you are taking any of the following:<br />&bull; Medicines used to treat asthma and colds (sympathomimetics) such as ephedrine and salbutamol<br />&bull; Non steroidal anti-inflammatory (NSAIDs) painkillers, such as indomethacin and ibuprofen<br />&bull; Medicines that make you pass more urine (diuretics) such as bendroflumethiazide and chlortalidone.<br />&bull; Nitrates, medicines used to treat chest pain (angina) and heart problems such as glycerol trinitrate and<br />isosorbide dinitrate<br />&bull; Procainamide, a medicine used to treat an irregular heartbeat<br />&bull; Aspirin (acetylsalicylic acid) and other medicines used to thin the blood<br />&bull; Any other medicines to treat high blood pressure e.g. beta-blockers such as propanolol and atenolol, or calcium<br />channel blockers such as amlodipine and nifedipine<br />&bull; Potassium supplements, salt substitutes containing potassium or any other medicines which can increase<br />potassium in your body, such as amiloride and spironolactone<br />&bull; Medicines used to treat diabetes (Insulins and sulphonylurea). Your dose may have to be adjusted while you are<br />taking Noyada Oral Solution<br />&bull; Lithium, a medicine used to treat a type of depression known as bipolar disorder<br />&bull; Medicines used for cancer treatment or in patients who had a transplantation, (cytostatic agents/<br />immunosuppressant agents), such as fluorouracil methotrexate, ciclosporin and azathioprine<br />&bull; Medicines used to treat depression and other mental health problems such as amitriptylline and<br />chlorpromazine. Taking these medicines with Noyada Oral Solution may make you feel dizzy or faint on standing<br />up from a seated position.<br />&bull; Allopurinol, a medicine used to treat gout<br />Your doctor may need to change your dose and/orto take other precautions:<br />If you are taking an angiotensin II receptor blocker (ARB) or aliskiren (see also information under the headings &lsquo;Do<br />not take Noyada Oral Solution&rsquo; and &lsquo;Warnings and precautions&rsquo;.<br />If you are due to have surgery<br />Before surgery and anaesthesia (even at the dentist) you should tell your doctor or dentist that you are taking<br />Noyada Oral Solution as there may be a sudden fall in your blood pressure.<br />Pregnancy, breast-feeding and fertility<br />Pregnancy<br />You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to<br />stop taking Noyada Oral Solution before you become pregnant or as soon as you know you are pregnant and will<br />advise you to take another medicine instead of Noyada Oral Solution. Noyada Oral Solution is not recommended<br />in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to<br />your baby if used after the third month of pregnancy.<br />Breast-feeding<br />Tell your doctor if you are breast-feeding or about to start breast-feeding. Breast-feeding newborn babies (first<br />few weeks after birth), especially premature babies, is not recommended whilst taking Noyada Oral Solution.<br />In the case of an older baby your doctor should advise you on the benefits and risks of taking Noyada Oral<br />Solution whilst breast-feeding, compared with other treatments.<br />Driving or using machines<br />Captopril can affect your ability to drive, usually when you first start taking your medicine or if your doctor&nbsp;changes your dose. If you do feel light-headed or dizzy when taking Noyada Oral Solution, you should not drive<br />or use machinery.<br />Noyada Oral Solution contains Sodium<br />Noyada 5mg/5ml Oral Solution contains 53.38 mg sodium per maximum daily dose. To be taken into consideration&nbsp;by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not<br />sure.<br />When you are taking Noyada Oral Solution you should not change to using any different captopril containing<br />medicines except under your doctor&rsquo;s supervision.<br />Elderly patients or patients with kidney disorders:<br />Your doctor may start you on a lower dose. If you have a kidney disorder your doctor will increase the dose<br />gradually until your blood pressure is adequately controlled up to a maximum of 150 mg per day.<br />The dosage may then be adjusted by your doctor to suit individual requirements.<br />For the treatment of high blood pressure:<br />The usual starting dose is 12.5 - 25 mg twice a day. Your doctor may gradually increase this dose to 100 - 150mg a<br />day. You may also need to be given other medicines to lower your blood pressure.<br />If you have kidney or heart problems or low levels of blood in your body you may be given a lower starting dose of<br />6.25mg or 12.5mg which may be gradually increased to 50mg -100mg a day.<br />For treatment in heart failure:<br />The usual starting dose is 6.25 &ndash; 12.5mg two or three times a day. Your doctor may gradually increase this dose to a<br />maximum of 150mg a day.<br />After a heart attack - short term treatment:<br />The usual starting dose is 6.25mg, which will then be gradually increased by your doctor to a maximum of 100mg<br />a day.<br />After a heart attack - long term treatment:<br />The usual starting dose is 6.25mg, which will then be gradually increased by your doctor to a maximum of 150mg<br />a day.<br />Use in diabetic patients:<br />The usual dose is 75 - 100mg a day. Elderly patients are usually started on a dose of 6.25mg twice daily.<br />Use in children:<br />Your doctor will prescribe the most appropriate strength of Noyada Oral Solution according to the child&rsquo;s<br />age, weight and dose.<br />Make sure that the correct amount is measured out.<br />The starting dose is 0.3mg/kg body weight, divided into 3 equal doses daily. This which may be increased<br />gradually by the doctor.<br />For children with kidney problems, premature babies and newborn babies and infants<br />The starting dose should be 0.15mg/kg body weight.<br />Make sure that the correct amount is measured out.<br />When to take Noyada Oral Solution<br />You should try to take Noyada Oral Solution at about the same time every day. As food does not affect how<br />captopril is absorbed, it can be taken before, during or after meals.</p><p>SHAKE WELL BEFORE USE.<br />Method of administration:<br />Your doctor, pharmacist or nurse will show you how to administer this medicine. The box containing this medicine<br />will contain a 1ml dosing syringe, a 5ml dosing syringe, and a dosing adaptor.<br />1ml syringe (orange barrel) each numbered increment is 0.1ml equivalent to 0.1mg captopril. The intermediate<br />increments are 0.05ml or 0.05mg of captopril.<br />5ml syringe (purple barrel) each numbered increment is 1ml equivalent to 1mg Noyada Oral Solution. The smaller<br />increments are 0.2ml or 0.2mg of the solution.<br />Instructions are provided below for using the dosing syringe. If you have any questions about the dose you should<br />use or how to use the syringe, you should ask your pharmacist.</p><p>Instructions for use:<br />&bull; Open the bottle: press the cap and turn it anticlockwise (figure 1)<br />&bull; Holding the bottle, take the plastic syringe adaptor from the box and insert the adaptor into the bottle neck<br />(figure 2).<br />Ensure it is well fixed.<br />&bull; Take the syringe and put it in the adaptor opening (figure 3).<br />&bull; Turn the bottle upside down.<br />&bull; Fill the syringe with a small amount of solution by pulling the piston down (figure 4a), then push the piston<br />upward in order to remove any possible bubble (figure 4b). Pull the piston down to the graduation mark<br />corresponding to the quantity in milliliters (ml) prescribed by your doctor (figure 4C).</p><p>&bull; Turn the bottle the right way up. Remove the syringe from the adaptor (figure 5).<br />&bull; Administer the contents of the syringe into the mouth by pushing the piston to the bottom of the syringe (figure<br />6) and ensure the medicine is swallowed.<br />&bull; Remove the adaptor from the bottle and close the bottle with the plastic screw cap.<br />&bull; Wash the adaptor and the syringe with warm water after use. Dry them with a clean paper towel and replace<br />them into the box with your medicine.<br />If you take more Noyada Oral Solution than you should<br />If you or any one else takes too much Noyada Oral Solution you should go to your nearest hospital emergency<br />department or tell your doctor immediately. Take the carton and bottle with any remaining solution you have with<br />you.<br />If you forget to take Noyada Oral Solution<br />If you miss a dose do not worry. Just carry on taking your normal dose when the next one is due. Do not take a<br />double dose to make up for the one you missed.<br />If you stop taking Noyada Oral Solution<br />You should not stop taking Noyada Oral Solution until your doctor tells you to, even if you feel well.<br />If you feel you need to stop taking this medicine you should discuss this with your doctor before you stop taking it.<br />If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Serious Side Effects<br />If you (or your child) experience any of the following reactions stop taking Noyada Oral Solution and<br />contact your doctor IMMEDIATELY:<br />&bull; Swelling of the hands, face, lips or tongue<br />&bull; Wheezing or difficulty in breathing<br />&bull; Ulcers, blistering and skin rashes or burning, red, peeling skin on the lips, tongue and genitals, sometimes<br />spreading to the eyes, face and body, (a very rare illness known as Stevens-Johnson syndrome)<br />&bull; Sore throat or fever<br />&bull; Severe dizziness or fainting<br />&bull; Serious chest pain that travels down your left arm<br />&bull; Fast, deep breathing, cold clammy skin and feelings of anxiety<br />&bull; Severe stomach pain<br />&bull; Yellowing of the skin and/or eyes<br />Other side effects<br />Common: May affect up to 1 in 10 people<br />&bull; Fits are observed in infants<br />&bull; Breathing problems in infant when asleep<br />&bull; Changes in posture in infants<br />&bull; Low urine amounts in premature infants<br />&bull; Weight loss in premature infants<br />&bull; Problems sleeping<br />&bull; Changes in the way things taste<br />&bull; Dizziness<br />&bull; Dry, irritating cough<br />&bull; Shortness of breath<br />&bull; Feeling or being sick<br />&bull; Indigestion or stomach pain<br />&bull; Diarrhoea or constipation<br />&bull; Dry mouth<br />&bull; Itching or a red rash<br />&bull; Hair loss<br />Uncommon: May affect up to 1 in 100 people<br />&bull; A fast or irregular heartbeat, or feeling your heart beat (palpitations)<br />&bull; Flushed or looking unusually pale<br />&bull; Low blood pressure. You may feel dizzy or faint<br />&bull; Painful, cold and discoloured fingers or toes caused by lack of blood to the area (Raynaud&rsquo;s syndrome)<br />&bull; Fatigue<br />&bull; A general feeling of being unwell<br />Rare: May affect up to 1 in 1,000 people<br />&bull; Loss of appetite<br />&bull; Drowsiness<br />&bull; Headache<br />&bull; Tingling, prickling or numbness of the skin<br />&bull; Pain and swelling inside the mouth<br />&bull; Mouth ulcers<br />&bull; Changes to your kidney function. Your doctor will carry out tests to check this<br />&bull; Changes in how often you pass urine<br />&bull; Stomach cramps, abdominal pain, or pain that moves from the stomach around to your back</p><p>Very Rare: May affect up to 1 in 10,000 people<br />&bull; Bleeding gums or nosebleeds<br />&bull; Swollen glands<br />&bull; Changes in your blood. Your doctor will carry out tests to check this<br />&bull; Changes in the amount of potassium, sodium and sugars in your blood. Your doctor will carry out tests to check<br />this<br />&bull; Confusion<br />&bull; Depression<br />&bull; Fainting<br />&bull; Blurred vision<br />&bull; Blocked nose<br />&bull; Chest tightness or a stabbing pain in your chest<br />&bull; Changes to your liver function or liver damage. Your doctor will carry out tests to check this<br />&bull; Itching and yellowing of the skin<br />&bull; Sensitivity to light<br />&bull; Muscle or joint pain<br />&bull; Difficulty achieving or maintaining an erection<br />&bull; Swelling of breast tissue in men (gynaecomastia)<br />&bull; Fever<br />&bull; Heart attack or heart shock</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not refrigerate. Store in the original package in order to protect from light.<br />Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP.<br />The expiry date refers to the last day of that month.<br />Do not store above 25&deg;C.<br />Use within 21 days of opening.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away<br />medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is captopril 5mg/5ml.<br />The other ingredients are disodium EDTA, sodium benzoate (E211), citric acid (E330), sodium citrate (E331) and&nbsp;purified water. May also contain sodium hydroxide (E524) for pH adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Noyada 5mg/5ml Oral Solution is a clear, colourless solution supplied in 100ml amber glass bottles. Each pack contains one bottle of solution, 1ml and 5ml dosing syringes and a syringe adaptor to fit onto the bottle when measuring the dose.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Martindale Pharamaceuticals Limited,<br />Bampton Road,<br />Harold Hill,<br />Romford,<br />Essex,<br />RM3 8UG,<br />United Kingdom</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي المحلول الفموي نويادا على المادة الفعالة كابتوبريل التي تنتمي إلى فئة من الأدوية تُسمى مثبطات الإنزيم المحول للإنجيوتنسن. تعمل مثبطات الإنزيم المحول للإنجيوتنسن من خلال المساعدة على توسيع الأوعية الدموية؛ مما يسهل على القلب ضخ الدمعبر الأوعية الدموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المرتفع وأمراض قلبية أخرى. إذا تُرك ضغط الدم المرتفع دون ضبط فمن الممكن أن يرفع من احتمال الإصابة بمرض قلبي أوسكتة. تعمل مادة كابتوبريل على خفض ضغط الدم مما يقلل من هذا الاحتمال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأشخاص الذين انخفضت لدهم كفاءة القلب في ضخ الدم. تُعرف هذه الحالة بـ &lt;&lt;فشل القلب&gt;&gt;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأشخاص الذين أُصيبوا بنوبة قلبية مؤخرًا. تحدث النوبة القلبية عند انسداد في أحد الأوعية الدموية الرئيسية الموصلة للدم إلى عضلة القلب. يعني هذا أن القلب لا يصل إليه الأكسجين الذي يحتاج إليه وتتلف عضلة القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الكًلية في الأشخاص المصابين بداء السكري.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم المحلول الفموي في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط الحساسية تجاه مادة كابتوبريل أو أيٍ من المكونات الأخرى في هذا الدواء (المذكورة في القسم 6 من هذه النشرة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أُصبت أنت أو أيً من أفراد أسرتك برد فعل في أي وقت مضى وكان مشتملاً على تورم اليدين أو الشفتين أو الوجه أو اللسان، ولم يكن السبب معلوماً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان المريض أنثى حاملاً تجاوزت الشهر الثالث من الحمل (يُفضل تجنب استخدام المحلول الفموي نويادا في مراحل الحمل الأولى) (انظري القسم &lt;&lt;الحمل&gt;&gt;).</p><p dir="RTL">أنت تُعاني من مرض السكر أو قصور في وظائف الكلى وتُعالج بدواء خافضٍ لضغط الدم يحتوي على الأليسكيرين.</p><p dir="RTL">أنت تُعاني من مرض السكر أو قصور في وظائف الكلى وتُعالج بدواء خافضٍ لضغط الدم يحتوي على الأليسكيرين.</p><p dir="RTL">إذا كانت أية حالة من الحالات المذكورة أعلاه تنطبق عليك أو على طفلك؛ فينبغي استشارة الطبيب قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحدث إلى الطبيب أو الممرض أوالصيدلي الخاص بك قبل تناول محلول نويادا الفموي،</strong></p><p dir="RTL">إذا كنت تتناول أي من الأدوية التالية المستخدمة في علاج ارتفاع ضغط الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات مستقبلات الأنجيوتينسن 2(المعروفة أيضًا باسم مجموعة سارتان، على سبيل المثال فالسارتان، تلميسارتان، إربيسارتان) وخاصةً إذا كنت تُعاني من مشاكل في الكلى مرتبطة بمرض السكر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأليسكيرين. قد يفحص طبيبك وظائف كليتك وضغط دمك ومقدار الشوارد (مثل البوتاسيوم) في دمك خلال فترات منتظمة.</p><p dir="RTL">انظر أيضًا المعلومات المدرجة تحت العنوان &lt;&lt;لا تناول محلول نويادا الفموي في الحالات التالية&gt;&gt;.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات </strong></p><p dir="RTL"><strong>ينبغي إخبار الطبيب في الحالات التالية: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان المريض أنثى تظن أنها حامل (أو قد تصبح) حاملاً. لا يُنصح باستخدام المحلول الفموي نويادا في بداية الحمل، ويجب ألا يؤخذ إذا كان الحمل تجاوز الأشهر الثلاثة الأولى، لأنه قد يسبب ضررًا خطيرًا على طفلك إذا استُخدم في تلك المرحلة (انظري قسم &lt;&lt;الحمل&gt;&gt;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الرضاعة الطبيعية أو التخطيط للرضاعة الطبيعية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تسير على نظام غذائي منخفض الملح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة استخدام مدرات البول (أقراص الماء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بقيء أو إسهال مفرط مؤخرًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة أخذ جلسات الدبال (الغسيل الكلوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بمشكلات في القلب خصوصًا في صمامات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالداء السكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بتورم الوجه أو العنق أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بتغيرات في لون البشرة وبياض العينين؛ يجب الذهاب إلى الطبيب فورًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستخضع لعملية جراحية في مستشفى أو ستذهب إلى طبيب الأسنان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بآلام في المعدة &ndash; فيجب إخبار الطبيب أن تستخدم المحلول الفموي نويادا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بتوعك، الإحساس بنبض القلب وضعف العضلات &ndash; قد يكون هذا بسبب ارتفاع نسبة البوتاسيوم في الدم لديك، وسيُجري لك الطبيب اختبار دم للتحقق من ذلك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>العلاج الكابت للمناعة</strong></p><p dir="RTL">إذا كنت تأخذ علاجًا كابتًا للمناعة؛ فقد يُجري لك الطبيب عددًا من الاختبارات أثناء العلاج بالمحلول الفموي نويادا للتأكد من عدم وجود علامات عدوى لديك. إذا بدأت أعراض عدوى معينة في الظهور عليك مثل التهاب الحلق أو الحمى؛ فيجب الاتصال بالطبيب فورًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مرضى الكُلى</strong></p><p dir="RTL">إذا كنت مصابًا بمرض الكلى فقد يُجري لك الطبيب عددًا من الاختبارات أثناء العلاج بالمحلول الفموي نويادا للتأكد من عدم وجود علامات عدوى لديك. إذا بدأت أعراض عدوى معينة في الظهور عليك مثل التهاب الحلق أو الحمى؛ فيجب الاتصال بالطبيب فورًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إزالة التحسس من لسع الزنابير</strong></p><p dir="RTL">إذا كنت ستأخذ علاج إزالة التحسس من أجل لسع الزنابير أو النحل؛ فينبغي إخبار الطبيب المعالج لك أنك تستخدم المحلول الفموي نويادا. في حالات نادرة؛ قد يحدث رد فعل تحسسي خطير إذا كنت تأخذ علاج إزالة التحسس أثناء استخدام هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الديال</strong></p><p dir="RTL">إذا كنت ستأخذ علاجًا لإزالة الكوليسترول من الدم بواسطة آلة (يُسمى هذا العلاج &lt;&lt;فصادة البروتين الشحمي خفيض الكثافة&gt;&gt; فينبغي إخبار الطبيب أنك تستخدم المحلول الفموي نويادا. قد تُعطى نوعًا مختلفًا من جلسات الديال أثناء استخدام هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>اختبارات الدم والبول</strong></p><p dir="RTL">يجب إخبار الطبيب أو الممرضة أنك تستخدم المحلول الفموي نويادا قبل إجراء أية اختبارات دم أو بول لأن هذا الدواء قد يؤثر في نتائج بعض الإختبارات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاختلافات العرقية</strong></p><p dir="RTL">إذا كنت من العرق الإفريقي الكاريبي؛ فقد تحتاج إلى جرعات أكبر من العادية من المحلول الفموي نويادا لخفض ضغط الدم لديك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>استخدام أدوية أخرى مع المحلول الفموي نويادا</strong></p><p dir="RTL">يُرجى إخبار الطبيب أو الصيدلي إذا كنت تستخدم حاليًا &ndash; أو استخدمت مؤخرًا &ndash; أية أدوية أخرى. هذا لأن المحلول الفموي نويادا يمكن أن يؤثر في مفعول بعض الأدوية الأخرى.</p><p dir="RTL">كما أن بعض الأدوية الأخرى يمكن أن يؤثر في مفعول المحلول الفموي</p><p dir="RTL">نويادا. ومن المهم بشكل خاص لإخبار الطبيب إذا كنت تستخدم أيًا من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الربو ونزلات البرد (محاكيات الودِّي) مثل إفيدرين وسالبوتامول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسكنات الألم من فئة مضادات الالتهاب غير السترويدية مثل إندوميثاسين وإيبوبروفين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدورة المدرة للبول (مدرات البول) مثل بندروفلوميثيازيد وكلورثاليدون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النترات، وهي أدوية مستخدمة لعلاك ألم الصدر (الذبحة) ومشكلات القلب مثل ثلاثي نترات الجليسرول وثنائي نترات الأيزوسوربيد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البروكايناميد، وهو دواء لعلاج اضطراب نبض القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأسبرين (حمض الأسيتيل ساليسيليك) والأدوية الأخرى المستخدمة لترقيق الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أية أدوية أخرى لعلاج ضغط الدم المرتفع مثل حاصرات بيتا مثل بروبانولول وأتينولول، أو حاصرات قنوات الكالسيوم مثل أملوديبين ونيفيدابين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات البوتاسيوم؛ وهي بدائل ملحية محتوية على البوتاسيوم، أو أية أدوية أخرى يمكن أن ترفع نسبة البوتاسيوم في الجسم مثل أميلوريد وسبيرونولاكتون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج داء السكري (أنواع الأنسولين والسالفونيل يوريا). قد تحتاج إلى تعديل جرعتك من هذه الأدوية أثناء استخدام المحلول الفموي نوياداد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج السرطان أو المرضى الذين خضعوا لعمليات زرع أعضاء، (العقاقير المانعة لنمو الخلايا / العقاقير الكابتة للمناعة)، مثل فلوروراسيل ميثوثريكسات وسيكلوسبورين وأزاثيوبرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الاكتئاب والاضطرابات النفسية الأخرى مثل أميتريبتلين وكلوربرومازين. قد يؤدي تعاطي هذه الأدوية مع المحلول الفموي نويادا إلى الشعور بالدوار والإغماء عند الوقوف من وضع الجلوس.</p><p dir="RTL"><strong>الوبيورينول، وهو دواء لعلاج النقرس.</strong></p><p dir="RTL"><strong>قد يحتاج طبيبك إلى تغيير الجرعة و/أو اتخاذ احتياطات أخرى:</strong></p><p dir="RTL">إذا كنت تتناول مضادات مستقبلات الأنجيوتينسن 2 أو الأليسكيرين (انظر أيضًا المعلومات المدرجة تحت العنوانين &lt;&lt;لا تناول محلول نويادا الفموي في الحالات التالية&gt;&gt; و &lt;&lt;التحذيرات والاحتياطات&gt;&gt;)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا كنت ستخضع لعملية جراحية</strong></p><p dir="RTL">قبل خضوع المريض لعملية جراحية وقبل التخدير (حتى لو عند طبيب الأسنان) يجب على المريض إخبار الطبيب أو طبيب الأسنان أنه يستخدم المحلول الفموي نويادا لأنه قد يحدث هبوط مفاجئ في ضغط الدم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب إخبار الطبيب إذا كانت المريضة حاملاً أو تصبح حاملاً. عادةً؛ سينصحك الطبيب بالتوقف عن استخدام المحلول الفموي نويادا قبل حدوث حمل أو فور العلم بحدوث الحمل، وسينصحك بتناول دواء أخر بدلا من المحلول الفموي نويادا. لا يُنصح باستخدام المحلول الفموي نويادا في بداية الحمل، ويُحظر أخذه إذا كان الحمل تجاوز الأشهر الثلاثة الأولى من الحمل، لأنه قد يسبب ضررًا خطيرًا على الطفل إذا استُخدم بعد الشهر الثالث من الحمل.</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">ينبغي إخبار الطبيب في حالة الرضاعة الطبيعية أو التخطيط للرضاعة الطبيعية. لا يوصى بالرضاعة الطبيعية للأطفال حديثي الولادة (الأسابيع القليلة الأولى بعد الولادة)، خصوصًا الأطفال المبتسرين أثناء استخدام الأم للمحلول الفموي نويادا.</p><p dir="RTL">في حالة الأطفال الأكبر سنًا؛ ينبغي للطبيب إعلام المريضة بفوائد ومخاطر استخدام المحلول الفموي نويادا أثناء الرضاعة الطبيعية، مقارنًة بالعلاجات الأخرى.</p><p dir="RTL"><strong>قيادة المركبات واستخدام الآلات</strong></p><p dir="RTL">يمكن أن تؤثر مادة كابتوبريل على القدرة على قيادة المركبات، وعادة يحدث ذلك عند بدء تناول الدواء لأول مرة أو عندما يغير الطبيب الجرعة. في حالة الشعور بدوخة أو دوار بعد استخدام المحلول الفموي نويادا؛ ينبغي عدم قيادة مركبات أو استخدام آلات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>احتواء المحلول الفموي نويادا على الصوديوم</strong></p><p dir="RTL">يحتوي المحلول الفموي نويادا 25 مجم/5 مل على 10.68 مجم من الصوديوم في الجرعة اليومية القصوى. ينبغي مراعاة هذا الأمر في المرضى الذين يسيرون على نظام غذائي قائم على التحكم في الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائمًا ينبغي استخدام هذا الدواء حسب إرشادات الطبيب تمامًا. ينبغي استشارة الطبيب أو الصيدلي في حالة عدم التأكد من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة استخدام المحلول الفموي نويادا؛ ينبغي للمريض عدم التغيير إلى استخدام أية أدوية أخرى محتوية على مادة كابتوبريل إلا تحت إشراف الطبيب المعالج.</p><p dir="RTL"><strong>المرضى المسنون أو المصابون باضطرابات كلوية:</strong></p><p dir="RTL">قد يصف الطبيب للمريض جرعة أقل من العادية. إذا كنت تعاني من اضطراب كلوي؛ فسيقوم الطبيب:</p><p dir="RTL">بزيادة الجرعة تدريجيًا حتى يتم ضبط ضغط الدم لديك بدرجة كافية، وبحد أقصى 150 مجم في اليوم.</p><p dir="RTL">بعد ذلك يمكن للطبيب ضبط الجرعة حسب حالة المريض الفردية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج ضغط الدم المرتفع:</strong></p><p dir="RTL">تتراوح جرعة البداية العادية من 12.5 إلى 25 مجم مرتين في اليوم. يمكن للطبيب زيادة هذه الجرعة تدريجيًا إلى 100 مجم</p><p dir="RTL">150 مجم في اليوم. يمكن أن يحتاج المريض أيضًا إلى أخذ أدوية أخرى لخفض ضغط الدم.</p><p dir="RTL">إذا كنت تعاني من مشكلات في الكلى أو القلب أو نقص مستويات الدم في الجسم؛ فقد تقل جرعة البداية إلى 6.25 مجم أو 12.5 مجم، ويمكن زيادة هذه الجرعة تدريجيًا إلى 50 مجم- 100 مجم في اليوم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للعلاج في حالة فشل القلب:</strong></p><p dir="RTL">تتراوح جرعة البداية العادية من 6.25 مجم إلى 12.5 مجم مرتين أو 3 مرات في اليوم. يمكن للطبيب زيادة هذه الجرعة تدريجيًا إلى 150 مجم في اليوم كحد أقصى.</p><p dir="RTL"><strong>بعد الإصابة بنوبة قلبية &ndash; العلاج قصير المدى:</strong></p><p dir="RTL">تكون جرعة البداية العادية 6.25 مجم، وبعد ذلك يمكن للطبيب زيادة هذه الجرعة تدريجيًا إلى 100 مجم في اليوم كحد أقصى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بعد الإصابة بنوبة قلبية &ndash; العلاج طويل المدى:</strong></p><p dir="RTL">تكون جرعة البداية العادية 6.25 مجم، وبعد ذلك يمكن للطبيب زيادة هذه الجرعة تدريجيًا إلى 150 مجم في اليوم كحد أقصى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاستخدام في مرضى السكري:</strong></p><p dir="RTL">تتراوح الجرعة العادية من 75 إلى 100 مجم في اليوم. وعادة يبدأ المسنون بأخذ جرعة 6.25 مجم مرتين في اليوم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاستخدام في الأطفال:</strong></p><p dir="RTL"><strong>سيصف الطبيب للطفل التركيز الأنسب من المحلول الفموي نويادا حسب عمر الطفل ووزنه والجرعة.</strong></p><p dir="RTL">يجب التأكد من معايرة المقدار الصحيح من الجرعة.</p><p dir="RTL">جرعة البداية هي 0.3 مجم/كجم من وزن الجسم، وتقسم إلى 3 جرعات متساوية في اليوم. يمكن للطبيب زيادة هذه الجرعة تدريجيًا.</p><p dir="RTL"><strong>الأطفال المصابون باضطرابات كلوية والمواليد المبتسرون والأطفال حديثو الولادة والرضع</strong></p><p dir="RTL">ينبغي أن تكون جرعة البداية 0.15 مجم/كجم من وزن الجسم. يجب</p><p dir="RTL">التأكد من معايرة المقدار الصحيح من الجرعة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>موعد أخذ جرعة المحلول الفموي نويادا</strong></p><p dir="RTL">ينبغي للمريض أن يحاول أخذ الجرعة الموصوفة له من المحلول الفموي نويادا في وقت محدد كل يوم. وحيث إن الطعام لا يؤثر على كيفية امتصاص مادة كابتوبريل؛ فيمكن أخذ الجرعة قبل الأكل أو أثنائه أو بعده.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>رج العبوة جيدًا قبل الاستخدام.</strong></p><p dir="RTL"><strong>طريقة الاستخدام:</strong></p><p dir="RTL">سيصف لك الطبيب أوالصيدلي أو الممرضة كيفية تناول هذا الدواء. ستجد في العلبة المحتوية على هذا الدواء محقنة معايرة سعتها 1مل ومحقنة معايرة جرعة&nbsp; سعتها 5مل وأداة ملئم الجرعات.</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:281.4pt;
 height:75pt' o:ole="">
 <v:imagedata src="file:///C:/Users/AZIZ~1.ALA/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="375" height="100" src="file:///C:/Users/AZIZ~1.ALA/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="PBrush" ShapeID="_x0000_i1025"
  DrawAspect="Content" ObjectID="_1707292408">
 </o:OLEObject>
</xml><![endif]--></p><p dir="RTL">حقنة 1مل (برميل برتقالي) كل زيادة مرقمة 0.1مل تعادل 0.1 ملجم كابتوبريل. الوسيط الزيادات 0.05مل أو 0.05ملجم من كابتوبريل.</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_i1026"
 type="#_x0000_t75" style='width:282pt;height:93.6pt' o:ole="">
 <v:imagedata src="file:///C:/Users/AZIZ~1.ALA/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
  o:title=""/>
</v:shape><![endif]--><img width="376" height="125" src="file:///C:/Users/AZIZ~1.ALA/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="PBrush" ShapeID="_x0000_i1026"
  DrawAspect="Content" ObjectID="_1707292409">
 </o:OLEObject>
</xml><![endif]--></p><p dir="RTL">في المحقنة حجم 5 مل (جسم المحقنة ألأرجواني اللون) كل علامة مرقمة تمثل زيادرة بمقدار 1 مل تعادل 1 مجم من المحلول الفموي نويادا. العلامات المرقمة الأصغر حجمًا تمثل زيادة بمقدار 0.2 مل أو 0.2 مجم من المحلول.</p><p dir="RTL">فيما يلي التعليمات الخاصة باستخدام محقنة معايرة الجرعة. إذا كان لديك أية أسئلة عن الجرعة التي يجب عليك أخذها أو عن كيفية استخدام المحقنة؛ فينبغي أن تسأل الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تعليمات الاستخدام:</strong></p><p dir="RTL">افتح الزجاجة: اضغط على الغطاء وأدره في عكس اتجاه عقارب الساعة (الشكل 1)</p><p dir="RTL">أثناء الإمساك بالزجاجة؛ خذ ملئم المحقنة البلاستيكي من العلبة وأدخل الملئم في عنق الزجاجة (الشكل 2) تأكد من التثبيت جيدًا.</p><p dir="RTL">خذ المحقنة وضعها في فتحة الملئم (الشكل 3). اقلب الزجاجة رأسًا على عقب.</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_i1027"
 type="#_x0000_t75" style='width:260.4pt;height:170.4pt' o:ole="">
 <v:imagedata src="file:///C:/Users/AZIZ~1.ALA/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="347" height="227" src="file:///C:/Users/AZIZ~1.ALA/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png" /><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="PBrush" ShapeID="_x0000_i1027"
  DrawAspect="Content" ObjectID="_1707292410">
 </o:OLEObject>
</xml><![endif]--></p><p dir="RTL">املأ المحقنة بمقدار صغير من المحلول من خلال سحب كباس المحقنة لأسفل (الشكل4أ)، ثم ادفع</p><p dir="RTL">الكباس لأعلى لإزالة أي فقاعات موجودة (الشكل 4ب). اسحب الكباس لأسفل إلى العلامة المرقمة المناظرة لمقدار الجرعة بالمليلترات (مل) التي وصفها لكل الطبيب (الشكل 4ج).</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_i1028"
 type="#_x0000_t75" style='width:258pt;height:169.8pt' o:ole="">
 <v:imagedata src="file:///C:/Users/AZIZ~1.ALA/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png"
  o:title=""/>
</v:shape><![endif]--><img width="344" height="226" src="file:///C:/Users/AZIZ~1.ALA/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png" /><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="PBrush" ShapeID="_x0000_i1028"
  DrawAspect="Content" ObjectID="_1707292411">
 </o:OLEObject>
</xml><![endif]--></p><p dir="RTL">أعد الزجاجة إلى وضعها الصحيح. أخرج المحقنة من الملئم (الشكل5).</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_i1029"
 type="#_x0000_t75" style='width:97.8pt;height:189pt' o:ole="">
 <v:imagedata src="file:///C:/Users/AZIZ~1.ALA/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
</v:shape><![endif]--><img width="130" height="252" src="file:///C:/Users/AZIZ~1.ALA/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png" /><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="PBrush" ShapeID="_x0000_i1029"
  DrawAspect="Content" ObjectID="_1707292412">
 </o:OLEObject>
</xml><![endif]--></p><p dir="RTL">تعاطى محتويات المحقنة في فمك عن طريق دفع كباس المحقنة إلى قاع المحقنة (الشكل 6) وتأكد من بلع الدواء.</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_i1030"
 type="#_x0000_t75" style='width:122.4pt;height:92.4pt' o:ole="">
 <v:imagedata src="file:///C:/Users/AZIZ~1.ALA/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png"
  o:title=""/>
</v:shape><![endif]--><img width="163" height="123" src="file:///C:/Users/AZIZ~1.ALA/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png" /><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="PBrush" ShapeID="_x0000_i1030"
  DrawAspect="Content" ObjectID="_1707292413">
 </o:OLEObject>
</xml><![endif]--></p><p dir="RTL">أخرج الملئم من الزجاجة وأغلق الزجاجة بالغطاء البلاستيكي الملولب.</p><p dir="RTL">اغسل الملئم والمحقنة بماء دافئ. جفف الملئم والمحقنة بفوطة ورقية نظيفة وأعدهما إلى مكانهما في العلبة مع الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة زائدة عن الموصوفة من المحلول الفموي نويادا</strong></p><p dir="RTL">إذا تناولت أنت أو أي شخص آخر جرعة مفرطة من المحلول الفموي نويادا؛ فينبغي الذهاب إلى قسم الطوائ في أقرب مستشفى لديك أو إخبار الطبيب بذلك فورًا. خذ علبة الدواء وزجاجة الدواء المحتوية على أية كمية متبقية من المحلول معك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في حالة نسيان جرعة المحلول الفموي نويادا</strong></p><p dir="RTL">في حالة نسيان جرعة، لا تقلق. عليك فقط الاستمرار في أخذ الجرعة الموصوفة لك في موعدها التالي عندما يحين. ينبغي عدم تناول جرعة مزدوجة لتعويض الجرعة الفائتة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في حالة التوقف عن أخذ جرعة المحلول الفموي نويادا</strong></p><p dir="RTL">ينبغي عدم التوقف عن تناول جرعة المحلول نويادا &ndash; حتى لو كنت تشعر يتحسن &ndash; إلا إذا أمر الطبيب بذلك. إذا شعرت بالرغبة في التوقف عن تناول هذا الدواء؛ فينبغي مناقشة هذا مع الطبيب قبل التوقف عن تناول الدواء.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فينبغي استشارة الطبيب أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL"><strong>إذا أُصبت أنت (أو طفلك) بأيٍ من ردود الأفعال التالية؛ فتوقف عن تناول المحلول الفموي نويادا واتصل بالطبيب فورًا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين أو الوجه أو الشفتين أو اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيز في الصدر أو صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحات، تنفط الجلد وطفوح جلدية أو حرق، تقشر واحمرار الجلد على الشفتين واللسان والأعضاء التناسلية، وأحيانًا ينتشر إلى العينين والوجه والجسم، (مرض نادر جدًا يُسمى متلازمة ستيفنز-جونسون)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق أو حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار شديد أو إغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في الصدر وينتقل إلى الذراع الأيسر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنفس سريع وعميق، برودة وعرق الجلد وشعور بالقلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد و/أو العينين</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تشمل الآثار الجانبية الأخرى ما يلي:</strong></p><p dir="RTL"><u>آثار شائعة: يمكن أن تؤثر في مريض واحد من كل 10 مرضى</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات ملحوظة في الأطفال الرضع</p><p dir="RTL">مشكلات في التنفس في الأطفال الرضع أثناء النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الوضع الجسمي في الأطفال الرضع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص كميات البول في الأطفال الرضع المبتسرين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الوزن في الأطفال الرضع المبتسرين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في مذاق الأطعمة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال تهيجي جاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان أو قيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر هضم أو ألم في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال أو إمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة أو طفح جلدي أحمر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقوط الشعر</p><p dir="RTL"><u>آثار غير شائعة: يمكن أن تؤثر في مريض واحد من كل 100 مريض</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة أو اضطراب نبض القلب أو الإحساس بنبض القلب (خفقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيغ أو شحوب غير عادي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط ضغط الدم. قد تشعر بدوخة أو إغماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بألم وبرودة في أصابع اليدين أوالقدمين وتغير لونها بسبب نقص الدم الواصل إلى هذه الأعضاء (متلازمة رينو)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور عام بالتوعك</p><p dir="RTL"><u>آثار جانبية نادرة: يمكن أن تؤثر في مريض واحد من كل 1000 مريض</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو تشوك أو نمل في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وتورم داخل الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قروح فموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في وظائف الكلى. سيُجري لك الطبيب اختبارات لفحص هذه الحالة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في عدد مرات التبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات في المعدة، ألم في البطن، أو ألم ينتقل من المعدة إلى الظهر.</p><p dir="RTL"><u>آثار نادرة جدًا: يمكن أن تؤثر في مريض واحد من كل 10000 مريض</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزف اللثة أو الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الغدد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الدم. سيُجري لك الطبيب اختبارات لفحص هذه الحالة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نسب البوتاسيوم والصوديوم والسكر في الدم. سيُجري لك الطبيب اختبارات لفحص هذه الحالة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيم الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق الصدر أو الإحساس يطعن في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في وظائف الكبد أو تلف الكبد. سيُجري لك الطبيب اختبارات لفحص هذه الحالة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة واصفرار الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية من الضوء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات أو المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة حدوث الانتصاب أو المحافظة عليه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أنسجة الصدر في الرجال (تثدي الرجال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية أو صدمة قلبية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب حفظ هذا الدواء بعيدًا عن متناول الأطفال ونظرهم. لا تضعه في الثلاجة.</p><p dir="RTL">يُخزن في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المكتوب على العلبة الكرتونية وملصق الزجاجة بعد الأحرف EXP. يشير تاريخ الصلاحية إلى آخر يوم في الشهر المطبوع.</p><p dir="RTL">لا يُحفظ في درجة حرارة أعلى من 25 درجة مئوية.</p><p dir="RTL">يُستخدم في غضون 21 يومًا من تاريخ فتح الزجاجة.</p><p dir="RTL">لا تتخلص من أي أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاج إليها. ستساعد هذه التعابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات المحلول الفموي نويادا</strong></p><p dir="RTL">المادة الفعالة. هي كابتوبريل 5 مجم/5 مل.</p><p dir="RTL">المكونات الأخرى هي: ملح ثنائي صوديوم ثنائي أمين الإيثيلين رباعي حمض الخل (إي دي تي أيه)، بنزوات صوديوم (إي211)، حمض ستريك (إي330)، ستريت صوديوم (إي331) وماء منقي. يمكن أن يحتوي المحلول أيضًا على هيدروكسيد الصوديوم (إي524) لتعديل الرقم الهيدروجيني.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل المحلول الفموي نويادا ومحتويات العبوة</strong></p><p dir="RTL">المحلول الفموي نويادا 5 مجم/5مل عبارة عن محلول رائق عديم اللون يأتي في زجاجات حجم 100 مل لونها عنبري. تحتوي كل عبوة على زجاجة محلول واحدة ومحقنة معايرة جرعة حجم 1 مل وأخرى جرعة حجم 5مل وملئم محقنة للتثبيت على الزجاجة عند معايرة الجرعة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة صاحبة تفويض التسويق والشركة المصنعة:</strong></p><p dir="RTL">Martindale Pharmaceuticals Limited,</p><p dir="RTL">Bampton Road, Harold Hill,</p><p dir="RTL">Romford, Essex,</p><p dir="RTL">RM3 8UG,</p><p dir="RTL">المملكة المتحدة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            كانون الثاني 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Noyada 5mg/5ml Oral Solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml of 5mg/5ml oral solution contains 1mg captopril.
This medicinal product contains 2.3 mmol (or 53.38 mg) sodium per maximum daily dose.
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral solution
Clear, colourless solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypertension: Noyada oral solution is indicated for the treatment of hypertension.<br />Heart Failure: Noyada oral solution is indicated for the treatment of chronic heart failure with reduction of systolic ventricular function, in combination with diuretics and, when appropriate, digitalis and beta-blockers.<br />Myocardial Infarction:<br />- short-term (4 weeks) treatment: Noyada oral solution is indicated in any clinically stable patient within the first 24 hours of an infarction.<br />- long-term prevention of symptomatic heart failure: Noyada oral solution is indicated in clinically stable patients with asymptomatic left ventricular dysfunction (ejection fraction equal to or below 40%).<br />Type I Diabetic Nephropathy: Noyada oral solution is indicated for the treatment of macroproteinuric diabetic nephropathy in patients with type I diabetes. (See section 5.1).<br />Noyada oral solution can be used alone or in combination with other antihypertensive agents (see sections 4.3, 4.4, 4.5 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dose should be individualised according to patient&rsquo;s profile (see section 4.4) and blood pressure response. The recommended maximum daily dose is 150 mg.<br />Noyada oral solution may be taken before, during and after meals.<br />Hypertension: the recommended starting dose is 25-50 mg daily in two divided doses. The dose may be increased incrementally, with intervals of at least 2 weeks, to 100-150 mg/day in two divided doses as needed to reach target blood pressure. Noyada oral solution may be used alone or with other antihypertensive agents, especially thiazide diuretics (see sections 4.3, 4.4, 4.5 and 5.1). A once-daily dosing regimen may be appropriate when concomitant antihypertensive medication such as thiazide diuretics is added.<br />In patients with a strongly active renin-angiotensin-aldosterone system (hypovolaemia, renovascular hypertension, cardiac decompensation) it is preferable to commence with a single dose of 6.25 mg or 12.5 mg. The inauguration of this treatment should preferably take place under close medical supervision. These doses will then be administered at a rate of two per day. The dosage can be gradually increased to 50 mg per day in one or two doses and if necessary to 100 mg per day in one or two doses.<br />Heart failure: treatment with captopril for heart failure should be initiated under close medical supervision. The usual starting dose is 6.25 mg - 12.5 mg BID or TID. Titration to the maintenance dose (75 - 150 mg per day) should be carried out based on patient&rsquo;s response, clinical status and tolerability, up to a maximum of 150 mg per day in divided doses. The dose should be increased incrementally, with intervals of at least 2 weeks to evaluate patient&rsquo;s response.</p><p>Myocardial infarction:<br />- short-term treatment: Captopril treatment should begin in hospital as soon as possible following the appearance of the signs and/or symptoms in patients with stable haemodynamics. A 6.25 mg test dose should be administered, with a 12.5 mg dose being administered 2 hours afterwards and a 25 mg dose 12 hours later. From the following day, captopril should be administered in a 100 mg/day dose, in two daily administrations, for 4 weeks, if warranted by the absence of adverse haemodynamic reactions. At the end of the 4 weeks of treatment, the patient&rsquo;s state should be reassessed before a decision is taken concerning treatment for the post-myocardial infarction stage.</p><p>- chronic treatment: if captopril treatment has not begun during the first 24 hours of the acute myocardial infarction stage, it is suggested that treatment be instigated between the 3rd and 16th day post-infarction once the necessary treatment conditions have been attained (stable haemodynamics and management of any residual ischaemia). Treatment should be started in hospital under strict surveillance (particularly of blood pressure) until the 75 mg dose is reached. The initial dose must be low (see section 4.4), particularly if the patient exhibits normal or low blood pressure at the initiation of therapy. Treatment should be initiated with a dose of 6.25 mg followed by 12.5 mg 3 times daily for 2 days and then 25 mg 3 times daily if warranted by the absence of adverse haemodynamic reactions. The recommended dose for effective cardioprotection during long-term treatment is 75 to 150 mg daily in two or three doses. In cases of symptomatic hypotension, as in heart failure, the dosage of diuretics and/or other concomitant vasodilators may be reduced in order to attain the steady state dose of captopril. Where necessary, the dose of captopril should be adjusted in accordance with the patient&rsquo;s clinical reactions. Captopril may be used in combination with other treatments for myocardial infarction such as thrombolytic agents, beta-blockers and acetylsalicylic acid.<br />Type I Diabetic nephropathy: in patients with type I diabetic nephropathy, the recommended daily dose of captopril is 75-100 mg in divided doses. If additional lowering of blood pressure is desired, additional antihypertensive medications may be added.<br />Renal impairment: since captopril is excreted primarily via the kidneys, dosage should be reduced or the dosage interval should be increased in patients with impaired renal function. When concomitant diuretic therapy is required, a loop diuretic (e.g. furosemide), rather than a thiazide diuretic, is preferred in patients with severe renal impairment.<br />In patients with impaired renal function, the following daily dose may be recommended to avoid accumulation of captopril.</p><p>(please refer to original SmPC for full table)&nbsp;</p><p>Creatinine clearance (ml/min/1.73 m2)<br />Daily starting dose (mg)<br />Daily maximum dose (mg)<br />&gt;40<br />25-50<br />150<br />21-40<br />25<br />100<br />10-20<br />12.5<br />75<br />&lt;10<br />6.25<br />37.5<br />Elderly patients: as with other antihypertensive agents, consideration should be given to initiating therapy with a lower starting dose (6.25 mg BID) in elderly patients who may have reduced renal function and other organ dysfunctions (see above and section 4.4).<br />Dosage should be titrated against the blood pressure response and kept as low as possible to achieve adequate control.</p><p>Paediatric Population<br />The efficacy and safety of captopril have not been fully established. The use of captopril in children and adolescents should be initiated under close medical supervision. The initial dose of captopril is about 0.3mg/kg body weight to be divided in 3 equal doses daily. For patients requiring special precautions (children with renal dysfunction, premature infants, new-borns and infants, because their renal function is not the same as older children and adults) the starting dose should be only 0.15mg captopril/kg weight. Generally, captopril is administered to children 3 times a day, but dose and interval of dose should be adapted individually according to patient&#39;s response.</p><p><br />Method of administration<br />For oral use only<br />Once titrated to an effective dose of Noyada Oral Solution, patients should remain on their treatment and extreme caution should be exercised when changing between different formulations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to captopril, to any other ACE inhibitor or to any of the excipients (see section 6.1)
- History of angioedema associated with previous ACE inhibitor therapy
- Hereditary/idiopathic angioneurotic oedema
- Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
- The concomitant use of Noyada oral solution with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypotension: rarely hypotension is observed in uncomplicated hypertensive patients. Symptomatic hypotension is more likely to occur in hypertensive patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea, vomiting or haemodialysis. Volume and/or sodium depletion should be corrected before the administration of an ACE inhibitor and a lower starting dose should be considered.<br />Patients with heart failure are at higher risk of hypotension and a lower starting dose is recommended when initiating therapy with an ACE inhibitor. Caution should be used whenever the dose of captopril or diuretic is increased in patients with heart failure.<br />As with any antihypertensive agent, excessive blood pressure lowering in patients with ischaemic cardiovascular or cerebrovascular disease may increase the risk of myocardial infarction or stroke. If hypotension develops, the patient should be placed in a supine position. Volume repletion with intravenous normal saline may be required.<br />Renovascular hypertension: there is an increased risk of hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with ACE inhibitors. Loss<br />of renal function may occur with only mild changes in serum creatinine. In these patients, therapy should be initiated under close medical supervision with low doses, careful titration and monitoring of renal function.</p><p>Renal impairment: in cases of renal impairment (creatinine clearance :S40 ml/min), the initial dosage of captopril must be adjusted according to the patient&#39;s creatinine clearance (see section 4.2), and then as a function of the patient&#39;s response to treatment. Routine monitoring of potassium and creatinine are part of normal medical practice for these patients.<br />Angioedema: angioneurotic oedema of the extremities, face, lips, mucous membranes, tongue, glottis and/or larynx may occur in patients treated with ACE inhibitors particularly during the first week of treatment. However, in rare cases, severe angioedema may develop after long-term treatment with an ACE inhibitor. Treatment should be discontinued promptly. Angioedema involving the tongue, glottis or larynx may be fatal. Emergency therapy should be instituted. The patient should be hospitalised and observed for at least 12 to 24 hours and should not be discharged until complete resolution of symptoms has occurred.<br />Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks.<br />Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see section 4.3 contraindications)<br />Intestinal angioedema has also been reported very rarely in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior facial angioedema and C- 1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan, or ultrasound or at surgery and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain (see section 4.8 undesirable effects).<br />Cough: cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-productive, persistent and resolves after discontinuation of therapy.</p><p>Dual blockade of the renin-angiotensin-aldosterone system (RAAS): There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.&rdquo;<br />Hepatic failure: rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood.<br />Patients receiving ACE inhibitors who develop jaundice or marked elevations of<br />hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.</p><p>Hyperkalaemia: elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including captopril. Patients at risk for the development of hyperkalaemia include those with renal insufficiency, diabetes mellitus, or those using concomitant potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes; or those patients taking other drugs associated with increases in serum potassium (e.g. heparin). If concomitant use of the above mentioned agents is deemed appropriate, regular monitoring of serum potassium is recommended.<br />Lithium: the combination of lithium and captopril is not recommended (see section 4.5)<br />Aortic and mitral valve stenosis / Obstructive hypertropic cardiomyopathy: ACE inhibitors should be used with caution in patients with left ventricular valvular and outflow tract obstruction and avoided in cases of cardiogenic shock and haemodynamically significant obstruction.<br />Neutropenia / Agranulocytosis: neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors, including captopril. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Captopril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections which in a few instances did not respond to intensive antibiotic therapy.<br />If captopril is used in such patients, it is advised that white blood cell count and differential counts should be performed prior to therapy, every 2 weeks during the first 3 months of captopril therapy, and periodically thereafter. During treatment all patients should be instructed to report any sign of infection (e.g. sore throat, fever) when a differential white blood cell count should be performed. Captopril and other concomitant medication (see section 4.5) should be withdrawn if neutropenia (neutrophils less than 1000/mm&sup3;) is detected or suspected.<br />In most patients neutrophil counts rapidly return to normal upon discontinuing captopril.</p><p>Proteinuria: proteinuria may occur particularly in patients with existing renal function impairment or on relatively high doses of ACE inhibitors.<br />Total urinary proteins greater than 1 g per day were seen in about 0.7% of patients receiving captopril. The majority of patients had evidence of prior renal disease or had received relatively high doses of captopril (in excess of 150 mg/day), or both. Nephrotic syndrome occurred in about one-fifth of proteinuric patients. In most cases, proteinuria subsided or cleared within six months whether or not captopril was continued. Parameters of renal function, such as BUN and creatinine, were seldom altered in the patients with proteinuria.<br />Patients with prior renal disease should have urinary protein estimations (dip- stick on first morning urine) prior to treatment, and periodically thereafter.<br />Anaphylactoid reactions during desensitisation: sustained life-threatening anaphylactoid reactions have been rarely reported for patients undergoing desensitising treatment with hymenoptera venom while receiving another ACE inhibitor. In the same patients, these reactions were avoided when the ACE<br />inhibitor was temporarily withheld, but they reappeared upon inadvertent rechallenge. Therefore, caution should be used in patients treated with ACE inhibitors undergoing such desensitisation procedures.</p><p>Anaphylactoid reactions during high-flux dialysis / lipoprotein apheresis membrane exposure: anaphylactoid reactions have been reported in patients haemodialysed with high-flux dialysis membranes or undergoing low-density lipoprotein apheresis with dextran sulphate absorption. In these patients, consideration should be given to using a different type of dialysis; membrane or a different class of medication.<br />Surgery/Anaesthesia: hypotension may occur in patients undergoing major surgery or during treatment with anaesthetic agents that are known to lower blood pressure. If hypotension occurs, it may be corrected by volume expansion. Diabetic patients: the glycaemia levels should be closely monitored in diabetic patients previously treated with oral antidiabetic drugs or insulin, namely during the first month of treatment with an ACE inhibitor.<br />Ethnic differences: as with other angiotensin converting enzyme inhibitors, captopril is apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.<br />Pregnancy:<br />ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, Drugs that act directly on the renin-angiotensin system can cause inJury and death to the developing fetus and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6)</p><p>Paediatric Population:<br />Neonates: The neonatal response to treatment with ACE inhibitors is very variable, and some neonates develop profound hypotension with even small doses; a test-dose should be used initially and increased cautiously. Adverse effects such as apnoea, seizures, renal failure, and severe unpredictable hypotension are very common in the first month of life and it is therefore recommended that ACE inhibitors are used with caution, particularly in preterm neonates.<br />Oliguria is a risk in premature patients treated with captopril.<br />Routine monitoring of infants on ACE inhibitors should include renal function tests, blood pressure and transcutaneous oxygen saturation measurements.<br />Older Children: As with neonates, older children can experience severe hypotension on administration of captopril. A small initial test dose should be administered with the patient supine, in order to avoid severe hypotension and tachycardia. As with adults hyperkalaemia may occur in conjunction with potassium sparing diuretics. Routine monitoring should include test for renal function. Dosages should be reduced in patients with impaired renal function. Leukopenia has been reported in children with renal impairment treated with captopril.</p><p>As Noyada Oral Solution does not contain a taste masking agent, there is the possibility of patient non-compliance, and this should be monitored to ensure proper dosing.<br />Noyada Oral Solution is available in two strengths 5mg/5ml and 25mg/5ml; caution is advised in ensuring that the correct strength is given to the patient. The doctor should prescribe the most appropriate strength based upon the clinical requirements of the patient (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Potassium sparing diuretics or potassium supplements: ACE inhibitors attenuate diuretic induced potassium loss. Potassium sparing diuretics (e.g. spironolactone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. If concomitant use is indicated because of demonstrated hypokalaemia they should be used with caution and with frequent monitoring of serum potassium (see section 4.4).<br />Diuretics (thiazide or loop diuretics): prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with captopril (see section 4.4). The hypotensive effects can be reduced by discontinuation of the diuretic, by increasing volume or salt intake or by initiating therapy with a low dose of captopril. However, no clinically significant drug interactions have been found in specific studies with hydrochlorothiazide or furosemide.<br />Other antihypertensive agents: captopril has been safely co-administered with other commonly used anti-hypertensive agents (e.g. beta-blockers and long- acting calcium channel blockers). Concomitant use of these agents may increase the hypotensive effects of captopril. Treatment with nitroglycerine and other nitrates, or other vasodilators, should be used with caution.<br />Alpha blocking agents: concomitant use of alpha blocking agents may increase the antihypertensive effects of captopril and increase the risk of orthostatic hypotension.<br />Treatments of acute myocardial infarction: captopril may be used concomitantly with acetylsalicylic acid (at cardiologic doses), thrombolytics, beta-blockers and/or nitrates in patients with myocardial infarction.<br />Lithium: reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide diuretics may increase the risk of lithium toxicity and enhance the already increased risk of lithium toxicity with ACE inhibitors. Use of captopril with lithium is not recommended, but if the&nbsp;combination proves necessary, careful monitoring of serum lithium levels should be performed (see section 4.4).<br />Tricyclic antidepressants / Antipsychotics: ACE inhibitors may enhance the hypotensive effects of certain tricyclic antidepressants and antipsychotics (see section 4.4). Postural hypotension may occur.<br />Allopurinol, procainamide, cytostatic or immuno-suppressive agents: concomitant administration with ACE inhibitors may lead to an increased risk for leucopenia especially when the latter are used at higher than currently recommended doses.<br />Non-steroidal anti-inflammatory medicinal products: it has been described that non-steroidal anti-inflammatory medicinal products (NSAIDs) and ACE inhibitors exert an additive effect on the increase in serum potassium whereas renal function may decrease. These effects are, in principle, reversible. Rarely, acute renal failure may occur, particularly in patients with compromised renal function such as the elderly or dehydrated. Chronic administration of NSAIDs may reduce the antihypertensive effect of an ACE inhibitor.<br />Sympathomimetics: may reduce the antihypertensive effects of ACE inhibitors; patients should be carefully monitored.<br />Antidiabetics: pharmacological studies have shown that ACE inhibitors, including captopril, can potentiate the blood glucose-reducing effects of insulin and oral antidiabetics such as sulphonylurea in diabetics. Should this very rare interaction occur, it may be necessary to reduce the dose of the antidiabetic during simultaneous treatment with ACE inhibitors.<br />Clinical Chemistry<br />Captopril may cause a false-positive urine test for acetone.<br />Clinical trial data has shown that dual blockade of the renin-angiotensin- aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy: When pregnancy is detected, discontinue captopril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause inJury and death to the developing fetus.The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning<br />pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.<br />Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (See section 5.3). Should exposure to ACE inhibitors have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p>Lactation:<br />Limited pharmacokinetic data demonstrate very low concentrations in breast milk (see section 5.2). Although these concentrations seem to be clinically irrelevant, the use of Noyada Oral Solution in breast-feeding is not recommended for preterm infants and for the first few weeks after delivery, because of the hypothetical risk of cardiovascular and renal effects and because there is not enough clinical experience.<br />In the case of an older infant, the use of Noyada Oral Solution in a breast- feeding mother may be considered if this treatment is necessary for the mother and the child is observed for any adverse effect.<br />Fertility:<br />No human fertility data are available. No evidence of impaired fertility was detected in animal studies (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other antihypertensives, the ability to drive and use machines may be reduced, namely at the start of the treatment, or when posology is modified, and also when used in combination with alcohol, but these effects depend on the individual&rsquo;s susceptibility.<br />- To reports any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334- 2340.<br />&bull; Toll free phone: 8002490000<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The table below lists adverse reactions reported with Captopril, ranked under the following frequency classification:<br />Very common (21/10); common (21/100 to &lt;1/10); uncommon (21/1,000 to<br />&lt;1/100); rare (21/10,000 to &lt;1/1,000), very rare (:S1/10,000), not known<br />(cannot be estimated from the available data).<br />Within each frequency, adverse reactions are presented in order of decreasing seriousness.<br />Table 1. Adverse reactions with Captopril in clinical trials and post-marketing experience</p><p>(Refer to original SmPC for full adverse reactions table 1)&nbsp;</p><p>Paediatric Population:<br />The major adverse events seen in the paediatric population were persistent dry cough, hyperkalemia, angioedema, decreased GFR, hypotension, neutropenia, impaired hepatic function and renal disorders.<br />The reactions most frequently observed during captopril therapy were headache, tachycardia, vomiting, postural symptoms, anaemia, rash and anorexia.<br />Adverse effects such as apnoea, seizures, renal failure, and severe unpredictable hypotension are very common in the first month of life and it is therefore recommended that ACE inhibitors are used with caution, particularly in preterm neonates (see section 4.4 Special Warnings and Precautions for use, Paediatric Population).<br />Oliguria is a risk in premature patients treated with captopril (see section 4.4 Special Warnings and Precautions for use, Paediatric Population).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of overdosage are severe hypotension, shock, stupor, bradycardia, electrolyte disturbances and renal failure.<br />After ingestion of an overdose, the patient should be kept under close supervision, preferably in an intensive care unit. Serum electrolytes and creatinine should be monitored frequently, as well as blood pressure. Therapeutic measures depend on the nature and severity of the symptoms.<br />Measures to prevent absorption (e.g. gastric lavage, administration of adsorbents and sodium sulphate within 30 minutes after intake) and hasten elimination should be applied if ingestion is recent. If hypotension occurs, the patient should be placed in the shock position and salt and volume supplementations should be given rapidly.<br />Treatment with angiotensin-II should be considered. Bradycardia or extensive vagal reactions should be treated by administering atropine. The use of a pacemaker may be considered.<br />Captopril may be removed from circulation by haemodialysis. The use of high-flux polyacrylonitrile membranes should be avoided. Naloxone has been used both successfully and unsuccessfully to reverse hypotension associated with captopril overdose</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ACE inhibitors, plain, ATC code: C09AA01<br />Captopril is a highly specific, competitive inhibitor of angiotensin-I converting enzyme (ACE inhibitors).<br />The beneficial effects of ACE inhibitors appear to result primarily from the suppression of the plasma renin-angiotensin-aldosterone system. Renin is an endogenous enzyme synthesised by the kidneys and released into the circulation where it converts angiotensinogen to angiotensin-I a relatively inactive decapeptide.<br />Angiotensin-I is then converted by angiotensin converting enzyme, a peptidyldipeptidase, to angiotensin-II. Angiotensin-II is a potent vasoconstrictor responsible for arterial vasoconstriction and increased blood pressure, as well as for stimulation of the adrenal gland to secrete aldosterone. Inhibition of ACE results in decreased plasma angiotensin-II, which leads to decreased vasopressor activity and to reduced aldosterone secretion. Although<br />the latter decrease is small, small increases in serum potassium concentrations may occur, along with sodium and fluid loss. The cessation of the negative feedback of angiotensin-II on the renin secretion results in an increase of the plasma renin activity.</p><p>Another function of the converting enzyme is to degrade the potent vasodepressive kinin peptide bradykinin to inactive metabolites. Therefore, inhibition of ACE results in an increased activity of circulating and local kallikrein-kinin-system which contributes to peripheral vasodilation by activating the prostaglandin system; it is possible that this mechanism is involved in the hypotensive effect of ACE inhibitors and is responsible for certain adverse reactions.<br />Reductions of blood pressure are usually maximal 60 to 90 minutes after oral administration of an individual dose of captopril. The duration of effect is dose related. The reduction in blood pressure may be progressive, so to achieve maximal therapeutic effects, several weeks of therapy may be required. The blood pressure lowering effects of captopril and thiazide-type diuretics are additive.<br />In patients with hypertension, captopril causes a reduction in supine and erect blood pressure, without inducing any compensatory increase in heart rate, nor water and sodium retention.<br />In haemodynamic investigations, captopril caused a marked reduction in peripheral arterial resistance. In general there were no clinically relevant changes in renal plasma flow or glomerular filtration rate. In most patients, the antihypertensive effect began about 15 to 30 minutes after oral administration of captopril; the peak effect was achieved after 60 to 90 minutes. The maximum reduction in blood pressure of a defined captopril dose was generally visible after three to four weeks.<br />In the recommended daily dose, the antihypertensive effect persists even during long-term treatment. Temporary withdrawal of captopril does not cause any rapid, excessive increase in blood pressure (rebound). The treatment of hypertension with captopril leads also to a decrease in left ventricular hypertrophy.</p><p>Haemodynamic investigations in patients with heart failure, showed that captopril caused a reduction in peripheral systemic resistance and a rise in venous capacity. This resulted in a reduction in pre-load and after-load of the heart (reduction in ventricular filling pressure). In addition, rises in cardiac output, work index and exercise capacity have been observed during treatment with captopril. In a large, placebo-controlled study in patients with left ventricular dysfunction (LVEF  40%) following myocardial infarction, it was shown that captopril (initiated between the 3rd to the 16th day after infarction) prolonged the survival time and reduced cardiovascular mortality. The latter was manifested as a delay in the development of symptomatic heart failure and a reduction in the necessity for hospitalisation due to heart failure compared to placebo. There was also a reduction in re-infarction and in cardiac<br />revascularisation procedures and/or in the need for additional medication with diuretics and/or digitalis or an increase in their dosage compared to placebo.<br />A retrospective analysis showed that captopril reduced recurrent infarcts and cardiac revascularisation procedures (neither were target criteria of the study).<br />Another large, placebo-controlled study in patients with myocardial infarction showed that captopril (given within 24 hours of the event and for duration of one month) significantly reduced overall mortality after 5 weeks compared to placebo. The favourable effect of captopril on total mortality was still detectable even after one year. No indication of a negative effect in relation to early mortality on the first day of treatment was found.</p><p>Captopril cardioprotection effects are observed regardless of the patient&rsquo;s age or gender, location of the infarction and concomitant treatments with proven efficacy during the post-infarction period (thrombolytic agents, beta-blockers and acetylsalicylic acid).<br />Type I diabetic nephropathy<br />In a placebo-controlled, multicentre double blind clinical trial in insulin- dependent (Type I) diabetes with proteinuria, with or without hypertension (simultaneous administration of other antihypertensives to control blood pressure was allowed), captopril significantly reduced (by 51%) the time to doubling of the baseline creatinine concentration compared to placebo; the incidence of terminal renal failure (dialysis, transplantation) or death was also significantly less common under captopril than under placebo (51%). In patients with diabetes and microalbuminuria, treatment with captopril reduced albumin excretion within two years.<br />The effects of treatment with captopril on the preservation of renal function are in addition to any benefit that may have been derived from the reduction in blood pressure.<br />Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.<br />These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers. ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Captopril is an orally active agent that does not require biotransformation for activity. The average minimal absorption is approximately 75%. Peak plasma concentrations are reached within 60-90 minutes. The presence of food in the gastrointestinal tract reduces absorption by about 30-40%. Approximately 25- 30% of the circulating drug is bound to plasma proteins.<br />The apparent elimination half-life of unchanged captopril in blood is about 2 hours. Greater than 95% of the absorbed dose is eliminated in the urine within 24 hours; 40-50% is unchanged drug and the remainder are inactive disulphide metabolites (captopril disulphide and captopril cysteine disulphide). Impaired renal function could result in drug accumulation. Therefore, in patients with impaired renal function the dose should be reduced and/or dosage interval prolonged (see section 4.2).<br />The peak plasma level of captopril after oral administration of the reference 25mg tablet was slightly higher than that observed after administration of the Noyada 25 mg/5 ml OralSolution in a single dose, randomised, crossover bioequivalence study with Cmax for Reference: 268.821&plusmn; 114.5752 ng/mL and Cmax for Noyada 25mg/5ml Oral Solution: 229.796 &plusmn; 60.9135 ng/mL.<br />Studies in animals indicate that captopril does not cross the blood-brain barrier to any significant extent.<br />Lactation:<br />In the report of twelve women taking oral captopril 100 mg 3 times daily, the average peak milk level was 4.7&mu;g/L and occurred 3.8 hours after the dose. Based on these data the maximum daily dosage that a nursing infant would receive is less than 0.002% of the maternal daily dosage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies performed during organogenesis with captopril have not shown any teratogenic effect but captopril has produced fetal toxicity in several species, including fetal mortality during late pregnancy, growth retardation and postnatal mortality in the rat. Captopril had no adverse effects on fertility of male and female rats at oral doses up to 1800 mg/kg/day. Preclinical data reveal no other specific hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicology, genotoxicity and carcinogenicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium EDTA</p><p>Sodium Benzoate E211</p><p>Citric Acid E330</p><p>Sodium Citrate E331<br />Sodium Hydroxide (pH adjuster)</p><p>Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months
Once open use within 21 days.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not refrigerate.<br />Do not store above 25&deg;C.<br />Store in the outer carton, in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber glass bottle with child resistant and tamper evident caps. Each bottle is packed in a cardboard carton containing 1ml and 5ml syringes with an adaptor along with a patient leaflet.<br />Pack size: 100ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Martindale Pharmaceuticals Limited (T/SMartindale Pharma) Bampton Road
Harold Hill Essex RM3 8UG
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                28/09/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>